Ipilimumab for Lymphoma
This study is evaluating whether ipilimumab in combination with ibrutinib or ibrutinib and nivolumab is safe and effective in treating patients with CLL and RT.
See full descriptionAbout the trial for Lymphoma
Treatment Groups
This trial involves 2 different treatments. Ipilimumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Lymphoma or one of the other 9 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Ipilimumab will improve 2 primary outcomes and 4 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of During first 21 days on study intervention.
Patient Q & A Section
What are common treatments for lymphoma?
What are they~ Chemotherapy and Radiotherapy are common treatments~ There are other options such as biopsies and surgery~ My best guess is, it is not uncommon~ If your symptoms are severe or if your lymphoma comes back after treatment
What causes lymphoma?
This is a complex cancer arising from the hematopoietic system. Many types of lymphomas have identifiable oncogenic mutations in tumor suppressor genes, and a number of these are already defined as well-characterized. Inappropriate use of TNF pathway inhibitors may contribute to lymphoma risk. The genetic architecture of Hodgkin disease, and for mantle-cell lymphoma, has recently been defined. Lymphoma is characterized by a B cell neoplastic clone, which leads to a defect in the antigen receptor or its corresponding cell-surface receptor. Other alterations include a defect in one or more tumor suppressor genes, which include CDKN2, MYC, and other genes that regulate progression through the cell cycle.
How many people get lymphoma a year in the United States?
About 100,000 people receive a diagnosis of lymphoma each year in the United States. Nearly 50,000 of them die from the disease within 5 years. Lymphoma is the second-leading cause of cancer-related death among men younger than 80.
What are the signs of lymphoma?
In the UK lymphoma is the leading cause of death in patients under the age of 50. Most cases of lymphoma are non--Hodgkin's disease and they are more common in women. The most common lymphoma in adults is lymphoma occurring mostly at an older age (mean 70 in England for lymphoma) and more commonly in men (mean 59 in England). Most individuals who develop lymphoma are asymptomatic. In England, the age-standardised rate per 100 000 population per year for all non-Hodgkin lymphoma cases is 9; and age-standardised rate for Hodgkin lymphoma is 5.
What is lymphoma?
Non-Hodgkin's lymphoma consists of two types: Diffuse large B-cell lymphoma and small lymphocytic leukemia. Non-Hodgkin's lymphoma usually starts in the elderly and generally has a poor prognosis.
Can lymphoma be cured?
The current data do not support any meaningful difference in overall or disease-free survival for men with early-stage, untreated low-grade follicular lymphoma after treatment with R-CHOP. Because high-grade follicular lymphoma is relatively chemotherapy-resistant, additional studies are needed and randomized trials should be considered when the treatment paradigm for follicular Lymphoma is being modified.
Have there been any new discoveries for treating lymphoma?
The number of studies on medical treatment for lymphomas is increasing. Most studies are small, and they do not produce the results that many people would like when examining research in the area of lymphoma treatment. Many people think that there is not much difference in the treatment of lymphoma, but that can't be true. There is no consensus in regards to staging lymphoma and treatment. Therefore, people are not sure if lymphoma treatments are effective when compared to another. At this point, it is hard to find research to prove that there is not enough research to decide on what treatment is better. The field of cancer research needs high-quality research before conclusions can be made.
How does ipilimumab work?
The data suggest that combination immunotherapies do not act as monotherapy. Rather, the addition of IPIs seems to increase the clinical benefit seen with the monotherapies and is a potentially meaningful addition to current chemotherapy regimens that rely heavily on antibodies. Data from a recent study also raise the possibility that, in some cases, antibody-based combination therapies may have synergistic effects that offset some of the toxic effects of chemotherapy.
Has ipilimumab proven to be more effective than a placebo?
Ipilimumab did not demonstrate superiority over a placebo regarding PFS or OS at 4 months. This underscores the absence of a role for TGF-β inhibitors in the treatment of indolent lymphoma.
What is the latest research for lymphoma?
This topic of a lymphoma cancer book is a complex topic. All I can recommend people to do is learn everything they can and then decide if that type of learning was beneficial in their lives. It pays to listen to your doctor and read all the books out there and then discuss anything in particular with your doctor. Good reading for medical knowledge includes books on cancer like the latest Cancer Management, the latest updates in cancer research by cancer researchers, Cancer Therapy as well as medical and surgical articles by doctors and/or research nurses. For lymphoma research, books and articles about lymphoma is good as cancer is highly complex and all types of cancer are under research for treatments and cures.
What is the survival rate for lymphoma?
The overall 5-year survival rate for patients with non-Hodgkin's lymphoma is 56.8%. The rate of mortality in elderly patients is 25.6%. There is a trend towards a better survival rate for low-grade B-cell lymphomas than for high-grade B-cell lymphomas. There is a trend towards a better survival rate for non-Hodgkin's lymphoma than for Hodgkin lymphoma.
What does ipilimumab usually treat?
Ipilimumab is a medication, which has been shown to show some improvement in symptoms in patients with [metastatic breast cancer](https://www.withpower.com/clinical-trials/metastatic-breast-cancer), by decreasing estrogen. Ipilimumab is also effective in treating patients with metastatic colorectal cancer, who had previously been treated with a fluoropyrimidine agent, if those patients have a mismatch repair deficiency or deficiencies in other DNA repair enzymes. Ipilimumab is approved for use in the following cancers: melanoma, head and neck cancer, renal cell cancer and non-small cell lung cancer.